Abstract: The sensors capable of measuring a wide range of pressures at high temperatures are critically needed in the industrial fields. We propose an optical fiber tip probe pressure sensor based on ...

FDA alerts and updates on the latest drug and device approvals, recalls, and other regulatory developments in ophthalmology.

At The Ohio State University Wexner Medical Center, we support a faculty member’s research and consulting in collaboration with medical device, research and/or drug companies because a faculty ...

A provider may be accepting new patients only in a specific specialty or location based on availability. A referral may be required. Accepting new patients I am a board-certified neurologist with ...

Oculis Holding AG recently reported that its neuroprotective candidate Privosegtor received U.S. FDA Breakthrough Therapy designation for optic neuritis, supported by positive Phase 2 ACUITY data and ...

Oculis Holding AG, a global biopharmaceutical company focused on breakthrough innovations to address significant unmet medical needs in neuro-ophthalmology and ophthalmology, announced that its ...

Optic neuritis, a common multiple sclerosis symptom, causes vision loss due to optic nerve inflammation. This experimental therapy aims to protect vision and nerve structure; a global Phase 3 trial is ...

Please provide your email address to receive an email when new articles are posted on . If approved, privosegtor would become the first neuroprotective therapy for optic neuropathies. The PIONEER 1 ...

Oculis Holding (OCS) added ~11% on Tuesday after the Swiss drug developer announced the breakthrough therapy designation for its eye disease therapy Privosegtor as a treatment for optic neuritis (ON), ...

Privosegtor is advancing in the registrational PIONEER program across 2 key optic neuropathies, representing an unaddressed potential market of $7 billion in the U.S. Privosegtor achieved an average ...